Multizentrische Therapiestudie: Multiples Myelom MM02 Abschlussbericht

Abstract

In a prospective randomized trial of the German Myeloma Treatment Group, 52 patients were treated for remission maintenance with #alpha#-interferon (3 Mio. U/x 3 weekly continuously) after successful induction therapy with either melphalan/prednisone (MivP) or VBAMDex chemotherapy. Neither the recurrence rate nor survival could be influenced by #alpha#-interferon maintenance treatment compared to the control group (n=64). It is concluded that maintenance therapy with #alpha#-interferon, at least at the chosen dose level, conveys no advantages to MM patients. (WEN)SIGLEAvailable from TIB Hannover: D.Dt.F.QN1(10,35)+a / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische InformationsbibliothekBundesministerium fuer Forschung und Technologie (BMFT), Bonn (Germany)DEGerman